Register Now To Attend The RDD Europe 2013 Scientific Conference To Be Held May 21-24, In Berlin, Germany
The Respiratory Drug Delivery (RDD) Europe 2013 scientific conference will welcome pulmonary and nasal drug delivery experts from all over the world to Berlin, May 21-24, 2013. The joint organizers of this prestigious event, RDD Online and Aptar Pharma, announce the opening of registration at: www.rddonline.com/rddeurope2013
A major scientific meeting for sharing knowledge about nasal and pulmonary drug delivery.
RDD conferences take place in both Europe and the USA in alternate years and are widely regarded as the premier venue for presenting the latest pulmonary and nasal drug delivery advances. After RDD 2012 which was held last May in Phoenix, Arizona, the upcoming RDD Europe 2013 is eagerly awaited. More than 450 delegates are expected to attend the May 21-24 meeting to be held at the Intercontinental Hotel Berlin, Germany. The scientific symposium will welcome an audience of high level academic, industrial and regulatory experts involved in the research, development, investigation, and marketing of existing and new therapies for delivery through the nose or lungs.
A three-day interactive symposium of the highest level
The meeting will begin with a plenary lecture titled “Biomarkers and Targeted Treatments for Small Airways Diseases – The Past, Present and Future” presented by Dr. D.S.Postma, M.D, Ph.D., Professor at the Department of Pulmonary Medicine and Tuberculosis, University Medical Centre Groningen, Groningen, The Netherlands.
The symposium will then focus on:
• Drug Development – New Drugs, Targets and Formulations
• Weighing the Evidence in Support of Bioequivalence
• Orphan drugs – Opportunities, Regulatory and Clinical Challenges
• Harmonizing the Clinical Requirements for LABA / ICS Combinations in the USA and Europe
• Designing Devices for the Marketplace
• Optimizing Formulation and Device Partnerships
As part of the event, RDD Europe conferences highlight innovative research contributions through podium and scientific poster sessions. These are enhanced by 12 technical interactive workshops from vendors and service providers in the industry. In all sessions, the latest technological advances related to nasal and pulmonary drug development will be presented.
Poster abstracts should be submitted via the conference website by January 11, 2013. RDD Europe 2013 also features an expanded high-profile exhibition showcasing the latest technologies and equipment in this exciting field.
RDD Europe 2013 offers numerous opportunities for networking, including a cocktail reception on the evening of May 21st and a gala dinner on May 23rd.
A previous conference delegate wrote, “Thank you. Great conference, good talks and discussion. Worthwhile to visit again.” We hope you visit RDD Europe 2013 too.
Previous RDD Europe events have been over-subscribed so early registration is strongly recommended.
Further details about RDD Europe 2013, as well as registration information, are available now at:
About RDD Online
RDD Online manages the organization of Respiratory Drug Delivery meetings in the US, and partners with Aptar Pharma to run RDD meetings in Europe. Other RDD Online services available at www.rddonline.com include the provision of scientific and technical publications, aerosol testing equipment including dose collection tubes and mixing inlets, web-based training, textbook publishing, service directories and recruiting services of interest to companies active in pulmonary and nasal drug delivery.. For more information, visit www.rddonline.com
About Aptar Pharma
Aptar Pharma is part of the Aptargroup family of companies, along with Aptar Beauty + Home and Aptar Food + Beverage. We create innovative drug delivery systems that meet the evolving needs of biotechnology, healthcare and pharmaceutical companies around the world. We provide our customers with a wide range of delivery technologies and analytical services backed by decades of proven expertise. For more information, visit www.aptar.com/pharma or www.aptar.com.
SOURCE: Aptar Pharma